Next Article in Journal
Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis—Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding
Next Article in Special Issue
Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2-∆∆Cq Method
Previous Article in Journal
Viscoelastic Hemostatic Assays: Moving from the Laboratory to the Site of Care—A Review of Established and Emerging Technologies
Previous Article in Special Issue
Diagnostic, Prognostic, and Therapeutic Value of Non-Coding RNA Expression Profiles in Renal Transplantation
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Diagnostics
Volume 10
Issue 2
10.3390/diagnostics10020119
diagnostics-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study

by
Yoshimasa Kosaka
1,
Yutaka Yamamoto
2,
Hirokazu Tanino
3,*,
Hiroshi Nishimiya
1,
Mutsuko Yamamoto-Ibusuki
4,
Yuko Hirota
5,
Hirotaka Iwase
2,
Seigo Nakamura
6 and
Sadako Akashi-Tanaka
6
1
Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
2
Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan
3
Division of Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
4
Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan
5
Department of Diagnostic Pathology, Showa University Koutou Toyosu Hospital, Koutou 135-8577, Japan
6
Department of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(2), 119; https://doi.org/10.3390/diagnostics10020119
Received: 29 December 2019 / Revised: 30 January 2020 / Accepted: 19 February 2020 / Published: 21 February 2020
(This article belongs to the Collection Biomarkers in Medicine)
View Full-Text Download PDF
Browse Figures
Review Reports

Abstract

Triple-negative breast cancer (TNBC) has several subtypes. The identification of markers associated with recurrence and poor prognosis in patients with TNBC is urgently needed. BRCAness is a set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation, or deletion, results in DNA repair deficiency. In the current study, we evaluated the clinical significance and prognosis of BRCAness in a multicenter retrospective study. Ninety-four patients with TNBC treated with neoadjuvant chemotherapy were enrolled from three university hospitals for this retrospective study. BRCAness was evaluated in 94 core needle biopsy (CNB) specimens prior to neoadjuvant chemotherapy and 49 surgical specimens without pathological complete response (pCR). The samples were assessed using multiplex ligation-dependent probe amplification, and the amplicons were scored. Of the 94 patients, 51 had BRCAness in CNB specimens. There were no significant differences in pCR rates or recurrence between the BRCAness and non-BRCAness groups. Among surgical specimens, the BRCAness group had a significantly shorter recurrence-free survival and overall survival compared with the non-BRCAness group. The BRCAness of surgical specimens was found to be an important marker to predict prognosis in patients with TNBC after neoadjuvant chemotherapy. A clinical trial to assess the clinical impact of carboplatin with BRCAness is planned. View Full-Text
Keywords: breast cancer; BRCAness; triple-negative breast cancer; neoadjuvant chemotherapy; prognosis breast cancer; BRCAness; triple-negative breast cancer; neoadjuvant chemotherapy; prognosis
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
SciFeed

Share and Cite

MDPI and ACS Style

Kosaka, Y.; Yamamoto, Y.; Tanino, H.; Nishimiya, H.; Yamamoto-Ibusuki, M.; Hirota, Y.; Iwase, H.; Nakamura, S.; Akashi-Tanaka, S. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics 2020, 10, 119. https://doi.org/10.3390/diagnostics10020119

AMA Style

Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics. 2020; 10(2):119. https://doi.org/10.3390/diagnostics10020119

Chicago/Turabian Style

Kosaka, Yoshimasa, Yutaka Yamamoto, Hirokazu Tanino, Hiroshi Nishimiya, Mutsuko Yamamoto-Ibusuki, Yuko Hirota, Hirotaka Iwase, Seigo Nakamura, and Sadako Akashi-Tanaka. 2020. "BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study" Diagnostics 10, no. 2: 119. https://doi.org/10.3390/diagnostics10020119

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop